Ono and Seikagaku Announce the Results from a Phase III Clinical Study in Japan of <br/>ONO-5704/SI-613 in Patients with Knee Osteoarthritis Presented at an Academic Conference | News Release

This link will direct you to a third-party site.（Another window opens.）

Please click here

Step back to the Seikagaku Corporation website

日本語

Who we are

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

Glycoscience in one minute

”Hyaluronic Acid” Expedition

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

R&D Basic Policy

R&D Pipeline

Sustainability

Sustainability Management

Materiality

Stakeholder Engagement

Environmental Policy

Environmental Impact Reduction Initiatives

Initiatives for Biodiversity

Information Disclosure Based on
the TCFD Recommendations

Social Contribution Activities

Human Resource Development

Diversity and Work-Life Balance

Corporate Governance

Compliance

Risk Management

Our Policy

ESG Data Book

External Evaluations

Materiality

Investors

News Release

What's New

Management Policy

Highlights

IR Library

IR Schedule

Shareholder Information

IR E-mail Alert

Message from President & CEO

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

Corporate Philosophy

Business Activities

Ono and Seikagaku Announce the Results from a Phase III Clinical Study in Japan of ONO-5704/SI-613 in Patients with Knee Osteoarthritis Presented at an Academic Conference

Ono and Seikagaku Announce the Results from a Phase III Clinical Study in Japan of
ONO-5704/SI-613 in Patients with Knee Osteoarthritis Presented at an Academic Conference